Boehringer Ingelheim has exercised the option to license a cystic fibrosis gene therapy in a collaboration with the UK 's Advanced Cancer Gene Therapy Consortium and Oxford BioMedica ( OXB ) to develop an inhaled , lentiviral vector - based treatment . Boehringer will provide funding , along with research and development , to move the therapy through preclinical studies , while OXB will provide expertise in lentiviral - based vector production . Boehringer 's option to acquire the global rights to the therapy can be exercised during the research and development process .
Boehringer Ingelheim has won the option to license a cystic fibrosis gene therapy in a collaboration with the UK's Cystic Fibrosis Gene Therapy Consortium and Oxford BioMedica (OXB) to develop an inhaled, lentiviral vector-based treatment. Boehringer will provide funding, along with research and development, to move the therapy through preclinical studies, while OXB will provide expertise in lentiviral-based vector production. Boehringer's option to obtain the global rights to the therapy can be exercised during the research and development process.